Stats by Source
Total, split by cell line (COSMIC CL / DepMap / PubMed) vs tissue (COSMIC primary tissue)
Total = all mutations for this gene across every source.
Cell line = COSMIC Cell Lines Project + DepMap + PubMed.
Tissue = COSMIC primary-tissue (patient tumour) samples.
Total can exceed cell line + tissue: COSMIC tissue-derived models sit only in global, and a peptide can be shared across both.
| Total | Cell line | Tissue | |
|---|---|---|---|
| Mutations | 1,233 | 154 | 1,074 |
| Samples | 585 | 93 | 489 |
| Peptides | 463 | 68 | 415 |
Function
DSC1 · Desmocollin 1
The protein encoded by this gene is a calcium-dependent glycoprotein that is a member of the desmocollin subfamily of the cadherin superfamily. These desmosomal family members, along with the desmogleins, are found primarily in epithelial cells where they constitute the adhesive proteins of the desmosome cell-cell junction and are required for cell adhesion and desmosome formation. A subtype of IgA pemphigus, a life-threatening autoimmune disease, is characterized by the presence of autoantibodies that target the encoded protein. The desmosomal family members are arranged in two clusters on chromosome 18. Alternative splicing of this gene results in multiple transcript variants. At least one of these variants encodes a preproprotein that is proteolytically processed to generate the mature protein. [provided by RefSeq, Nov 2015].
Isoforms & Proteins
2 transcripts · UniProt mapping is sequence-verified (AA-safe)
Each Ensembl transcript (ENST) this gene is mutated on, with its matched UniProt accession.
The mapping is sequence-verified: the UniProt sequence is identical to the transcript translation, so amino-acid positions line up exactly. A * marks an unreviewed (TrEMBL) entry.
Counts are mutations and unique mutant peptides on each transcript.
Gene Properties
Recurrent Mutations
All 456 amino-acid changes on canonical ENST00000257198 · needle height = samples · drag the mini-map to zoom
A lollipop / needle plot – the standard way to show recurrent mutations along a protein (as used by cBioPortal and MutationMapper).
X-axis = amino-acid position in the protein.
Needle height & head size = how often that exact amino-acid change was observed (its recurrence). Tall/large heads are mutational hotspots.
The most recurrent changes are labelled; hover any needle for the change, position and counts.
Mutation frequency across cancer types
% of samples with a missense/complex mutation in DSC1 · cell line vs tissue
For each cancer type, the fraction of samples that carry at least one missense/complex mutation anywhere in DSC1 – counted as distinct samples (a sample counts once no matter how many mutations it has).
Split into cell line and tissue; each cell shows mutated / total and the percentage. Cohorts with <20 samples are omitted. Ordered by combined frequency.
| Cancer type | Cell lines | Tissue samples |
|---|---|---|
| T-Lymphoblastic Leukemia | 7/40 18% | 0/0 0% |
| T-Cell Non-Hodgkins Lymphoma | 3/26 12% | 0/0 0% |
| Melanoma | 15/210 7% | 164/1899 9% |
| Chronic Myelogenous Leukemia | 2/25 8% | 0/0 0% |
| Endometrial Carcinoma | 2/42 5% | 29/612 5% |
| Gastrointestinal Stromal Tumour | 0/0 0% | 4/133 3% |
| Squamous Cell Lung Carcinoma | 4/57 7% | 18/810 2% |
| Non-Small Cell Lung Carcinoma | 13/304 4% | 27/1390 2% |
| Colorectal Carcinoma | 10/143 7% | 46/3239 1% |
| Small Cell Lung Carcinoma | 0/9 0% | 11/752 1% |
| Cervical Carcinoma | 0/35 0% | 6/422 1% |
| Glioblastoma | 1/98 1% | 0/0 0% |
| Other Solid Cancers | 1/94 1% | 15/1515 1% |
| Bladder Carcinoma | 0/58 0% | 10/956 1% |
| Gastric Carcinoma | 0/74 0% | 17/1809 1% |
| Hepatocellular Carcinoma | 3/46 7% | 17/2210 1% |
| Burkitts Lymphoma | 2/32 6% | 0/196 0% |
| Adrenocortical Carcinoma | 0/3 0% | 1/112 1% |
| Non-Cancerous | 2/104 2% | 6/830 1% |
| Neuroendocrine Tumour | 5/154 3% | 1/577 0% |
| Other Sarcomas | 1/69 1% | 5/699 1% |
| Hodgkins Lymphoma | 0/16 0% | 1/122 1% |
| Ovarian Carcinoma | 0/109 0% | 8/998 1% |
| Head and Neck Carcinoma | 2/85 2% | 9/1574 1% |
| Esophageal Squamous Cell Carcinoma | 0/51 0% | 17/2550 1% |
| B-Cell Non-Hodgkins Lymphoma | 2/88 2% | 14/2534 1% |
| Plasma Cell Myeloma | 0/44 0% | 2/305 1% |
| Kidney Carcinoma | 6/85 7% | 5/1862 0% |
| Germ Cell Tumour | 1/25 4% | 0/169 0% |
| Glioma | 1/52 2% | 10/2127 0% |
Mutation Distribution
Where DSC1 is mutated · all tissues, split by cell line vs tissue
How many mutations in DSC1 were found in each tissue, across the whole database.
Each bar is a tissue (cell-line and tissue names are merged to the standard tissue), split into cell line and tissue (patient tumour) contributions.
This shows the cancer-context where this gene is recurrently altered.
GTEx Expression
Median TPM across 53 healthy tissues
Median gene expression (TPM) in normal, non-cancer human tissues from the GTEx project.
Useful for judging tumour specificity – a strong neoantigen target ideally comes from a gene with low expression in healthy tissues.
Scroll or drag the mini-axis below the chart to browse all tissues.
Mutations
All 1,233 mutations in DSC1
Every mutation record for this gene, across all samples and sources.
The Sample column links to the cell line (cell-line samples) or the tissue type (tissue samples).
Use the Type / Source filters, the search box, and column sorting to explore; each CAN-IMMUNE ID opens the full mutation & peptide view.
| ID | Sample | Transcript | AA Change | CDS | Type | Source | Mutant Peptide | Wild-type Peptide |
|---|